Form 8-K Filing - Appointment of Executive Director

Silence Therapeutics plc announced on December 18, 2025, the appointment of Rhonda Hellums, the Company’s Executive Vice President and Chief Financial Officer, to the Board of Directors. Ms. Hellums will serve an initial term ending at the conclusion of the Company’s 2026 Annual General Meeting of Shareholders. As an executive director, she will not be appointed to any board committees or receive additional compensation for her board service. There are no undisclosed arrangements, understandings, or family relationships between Ms. Hellums and other company directors or officers, nor does she have a material interest in any disclosable transactions. Her biography was previously filed in the Company’s definitive proxy statement on May 16, 2025.